The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Medical ethicists have discussed the use of race classification in determining disease prevalence and the response of specific ethnic groups to different medications.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
Prashasti Bhatnagar joins Ethics Talk to discuss her article, coauthored with Dr Deborah F. Perry and Margaret E. Greer: “How Should We Measure Effectiveness of Medical-Legal Partnerships?”